|Elimination half-life||70 hrs|
|Excretion||79% faeces, 3% urine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||469.95 g·mol−1|
|3D model (JSmol)|
Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing[when?].
Dacomitinib was approved in the United States in 2018, in Japan in 2019 and in the European Union (EU) authorized by the European Medicines Agency (EMA) in 2019  for the treatment of non-small cell lung cancer with EGFR gene mutation.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|